Literature DB >> 29177926

Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma?

Linda M Pak1, Mithat Gonen2, Kenneth Seier2, Vinod P Balachandran1, Michael I D'Angelica1, William R Jarnagin1, T Peter Kingham1, Peter J Allen1, Richard K G Do3, Amber L Simpson4.   

Abstract

PURPOSE: Clinician gestalt may hold unexplored information that can be capitalized upon to improve existing nomograms. The study objective was to evaluate physician ability to predict 2-year overall survival (OS) in resected pancreatic ductal adenocarcinoma (PDAC) patients based on pre-operative clinical characteristics and routine CT imaging.
METHODS: Ten surgeons and two radiologists were provided with a clinical vignette (including age, gender, presenting symptoms, and pre-operative CA19-9 when available) and pre-operative CT scan for 20 resected PDAC patients and asked to predict the probability of each patient reaching 2-year OS. Receiver operating characteristic curves were used to assess agreement and to compare performance with an established institutional nomogram.
RESULTS: Ten surgeons and 2 radiologists participated in this study. The area under the curve (AUC) for all physicians was 0.707 (95% CI 0.642-0.772). Attending physicians with > 5 years experience performed better than physicians with < 5 years of clinical experience since completion of post-graduate training (AUC = 0.710, 95% CI [0.536-0.884] compared to AUC = 0.662, 95% CI [0.398-0.927]). Radiologists performed better than surgeons (AUC = 0.875, 95% CI [0.765-0.985] compared to AUC = 0.656, 95% CI [0.580-0.732]). All but one physician outperformed the clinical nomogram (AUC = 0.604).
CONCLUSIONS: This pilot study demonstrated significant promise in the quantification of physician gestalt. While PDAC remains a difficult disease to prognosticate, physicians, particularly those with more clinical experience and radiologic expertise, are able to perform with higher accuracy than existing nomograms in predicting 2-year survival.

Entities:  

Keywords:  Nomogram; Pancreatic adenocarcinoma; Prediction; Survival

Mesh:

Substances:

Year:  2018        PMID: 29177926      PMCID: PMC5967975          DOI: 10.1007/s00261-017-1407-x

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  35 in total

1.  Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma.

Authors:  Alessandro Paniccia; Patrick Hosokawa; William Henderson; Richard D Schulick; Barish H Edil; Martin D McCarter; Csaba Gajdos
Journal:  JAMA Surg       Date:  2015-08       Impact factor: 14.766

2.  A Pilot Study Evaluating Serum MMP7 as a Preoperative Prognostic Marker for Pancreatic Ductal Adenocarcinoma Patients.

Authors:  Sam C Wang; Justin R Parekh; Matthew R Porembka; Hari Nathan; Michael I D'Angelica; Ronald P DeMatteo; Yuman Fong; T Peter Kingham; William R Jarnagin; Peter J Allen
Journal:  J Gastrointest Surg       Date:  2016-02-26       Impact factor: 3.452

3.  Learning Curve for Laparoscopic Pancreaticoduodenectomy: a CUSUM Analysis.

Authors:  Mingjun Wang; Lingwei Meng; Yunqiang Cai; Yongbin Li; Xin Wang; Zhaoda Zhang; Bing Peng
Journal:  J Gastrointest Surg       Date:  2016-02-22       Impact factor: 3.452

4.  Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.

Authors:  Shinichi Yachida; Catherine M White; Yoshiki Naito; Yi Zhong; Jacqueline A Brosnan; Anne M Macgregor-Das; Richard A Morgan; Tyler Saunders; Daniel A Laheru; Joseph M Herman; Ralph H Hruban; Alison P Klein; Siân Jones; Victor Velculescu; Christopher L Wolfgang; Christine A Iacobuzio-Donahue
Journal:  Clin Cancer Res       Date:  2012-09-18       Impact factor: 12.531

5.  Resectable pancreatic adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting pathology and patient outcomes.

Authors:  Christophe Cassinotto; Jaron Chong; George Zogopoulos; Caroline Reinhold; Laurence Chiche; Jean-Pierre Lafourcade; Adeline Cuggia; Eric Terrebonne; Anthony Dohan; Benoît Gallix
Journal:  Eur J Radiol       Date:  2017-02-22       Impact factor: 3.528

6.  Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival.

Authors:  Cristina R Ferrone; Michael W Kattan; James S Tomlinson; Sarah P Thayer; Murray F Brennan; Andrew L Warshaw
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

Review 7.  Pathologic staging of pancreatic, ampullary, biliary, and gallbladder cancers: pitfalls and practical limitations of the current AJCC/UICC TNM staging system and opportunities for improvement.

Authors:  N Volkan Adsay; Pelin Bagci; Takuma Tajiri; Irma Oliva; Nobuyuki Ohike; Serdar Balci; Raul S Gonzalez; Olca Basturk; Kee-Taek Jang; Juan Carlos Roa
Journal:  Semin Diagn Pathol       Date:  2012-08       Impact factor: 3.464

8.  Validation of a nomogram for predicting survival after resection for adenocarcinoma of the pancreas.

Authors:  S M M de Castro; S S A Y Biere; S M Lagarde; O R C Busch; T M van Gulik; D J Gouma
Journal:  Br J Surg       Date:  2009-04       Impact factor: 6.939

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Does resident experience affect outcomes in complex abdominal surgery? Pancreaticoduodenectomy as an example.

Authors:  Daniel M Relles; Richard A Burkhart; Michael J Pucci; Jocelyn Sendecki; Renee Tholey; Ross Drueding; Patricia K Sauter; Eugene P Kennedy; Jordan M Winter; Harish Lavu; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2013-11-13       Impact factor: 3.452

View more
  2 in total

1.  Prognostic Imaging Biomarkers for Pancreatic Ductal Adenocarcinoma Extracted from Structured Radiologist Reports.

Authors:  Nikita Consul
Journal:  Radiol Imaging Cancer       Date:  2020-11-27

2.  MRI radiomics for early prediction of response to vaccine therapy in a transgenic mouse model of pancreatic ductal adenocarcinoma.

Authors:  Aydin Eresen; Jia Yang; Junjie Shangguan; Yu Li; Su Hu; Chong Sun; Yury Velichko; Vahid Yaghmai; Al B Benson; Zhuoli Zhang
Journal:  J Transl Med       Date:  2020-02-10       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.